Despite expectations of dealmaking leniency, new FTC chairman Andrew Ferguson told staff that he will retain the current 2023 ...

Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in ...

FYB202 is an interleukin inhibitor that can be used in dermatology to treat psoriasis and in gastroenterology to treat chronic inflammatory bowel disease. The biosimilar received marketing ...

Charles River's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. The company ended 2024 with about $195 million in cash, and it recorded a ...

Foods IBS Provides Personalized Diet Therapy for Patients Suffering with Irritable Bowel Syndrome (IBS) Research Finds Patients Following a Personalized Diet Therapy Created wit ...

Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...

Last week, the NIH abruptly changed its funding rules for scientific research, prompting chaos and uncertainty for scientific researchers everywhere, including in cancer research clinical trials.

But we agreed that when we filed this impeachment complaint, na kung bubuksan ng senado ang impeachment trial, dapat desidido kaming magpapatuloy ng aming prosecution [that if the Senate opens the ...

Dr. Hing C. Wong, founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially ...

DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence-based Clinical Trial Solutions for Patient Matching - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's ...